IL290586B2 - Thrombosomes as an antiplatelet agent reversal agent - Google Patents

Thrombosomes as an antiplatelet agent reversal agent

Info

Publication number
IL290586B2
IL290586B2 IL290586A IL29058622A IL290586B2 IL 290586 B2 IL290586 B2 IL 290586B2 IL 290586 A IL290586 A IL 290586A IL 29058622 A IL29058622 A IL 29058622A IL 290586 B2 IL290586 B2 IL 290586B2
Authority
IL
Israel
Prior art keywords
composition
platelets
subject
agent
incubating
Prior art date
Application number
IL290586A
Other languages
English (en)
Hebrew (he)
Other versions
IL290586B1 (en
IL290586A (en
Original Assignee
Cellphire Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellphire Inc filed Critical Cellphire Inc
Publication of IL290586A publication Critical patent/IL290586A/en
Publication of IL290586B1 publication Critical patent/IL290586B1/en
Publication of IL290586B2 publication Critical patent/IL290586B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL290586A 2019-08-16 2020-08-14 Thrombosomes as an antiplatelet agent reversal agent IL290586B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962887923P 2019-08-16 2019-08-16
US202063065337P 2020-08-13 2020-08-13
PCT/US2020/046525 WO2021034719A1 (en) 2019-08-16 2020-08-14 Thrombosomes as an antiplatelet agent reversal agent

Publications (3)

Publication Number Publication Date
IL290586A IL290586A (en) 2022-04-01
IL290586B1 IL290586B1 (en) 2025-08-01
IL290586B2 true IL290586B2 (en) 2025-12-01

Family

ID=74568065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290586A IL290586B2 (en) 2019-08-16 2020-08-14 Thrombosomes as an antiplatelet agent reversal agent

Country Status (10)

Country Link
US (3) US11701388B2 (de)
EP (1) EP4013496A4 (de)
JP (1) JP7791581B2 (de)
KR (1) KR20220054329A (de)
CN (1) CN114450066A (de)
AU (2) AU2020334903B2 (de)
BR (1) BR112022002892A2 (de)
CA (1) CA3150936A1 (de)
IL (1) IL290586B2 (de)
WO (1) WO2021034719A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
AU2019387368A1 (en) 2018-11-30 2021-06-17 Cellphire, Inc. Platelets as delivery agents
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
CA3150936A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
WO2022178177A1 (en) * 2021-02-17 2022-08-25 Cellphire, Inc. Freeze-dried platelet derivative compositions for treating antiplatelet-induced coagulopathy
EP4013432A4 (de) * 2019-08-16 2023-10-18 Cellphire Inc. Thrombosomen als mittel zur aufhebung der gerinnungshemmenden wirkung
CA3170198A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
US20220273724A1 (en) 2021-02-17 2022-09-01 Cellphire Inc. Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof
CN115737814B (zh) * 2022-10-26 2024-06-21 中国科学院大学 抗血小板药物及制备方法、抗血小板药物捕获剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0967862A1 (de) * 1997-02-07 2000-01-05 Quadrant Holdings Cambridge Limited Verfahren und zusammensetzungen zur herstellung getrockneter, lagerungsstabiler blutplättchen
US8486617B2 (en) * 2004-08-12 2013-07-16 Cellphirc, Inc Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932943A (en) 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
US3928566A (en) 1970-08-14 1975-12-23 Du Pont Lyophilized biological products
DE2546166A1 (de) 1975-10-15 1977-04-28 Behringwerke Ag Gegerbte thrombozyten
US4059967A (en) 1976-02-19 1977-11-29 The Community Blood Council Of Greater New York, Inc. Process for freezing blood platelets
US4455299A (en) 1981-11-20 1984-06-19 Baxter Travenol Laboratories, Inc. Storage of blood platelets
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4670013A (en) 1982-12-27 1987-06-02 Miles Laboratories, Inc. Container for blood and blood components
US4865871A (en) 1983-08-23 1989-09-12 Board Of Regents The University Of Texas System Method for cryopreparing biological tissue
US5185160A (en) 1984-06-21 1993-02-09 Prp, Inc. Platelet membrane microvesicles
EP0383363A3 (de) 1984-11-29 1990-10-03 Regents Of The University Of Minnesota Verwendung von Wundheilungsagentien
US5213814A (en) 1989-04-10 1993-05-25 Cryopharm Corporation Lyophilized and reconstituted blood platelet compositions
US5958670A (en) 1988-05-18 1999-09-28 Cobe Laboratories, Inc. Method of freezing cells and cell-like materials
US4994367A (en) 1988-10-07 1991-02-19 East Carolina University Extended shelf life platelet preparations and process for preparing the same
US5059518A (en) 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
DE68918083T2 (de) 1988-11-18 1995-01-05 Tosoh Corp Verfahren zur reinigung von blutplasma.
US5332578A (en) 1989-04-14 1994-07-26 Prp, Inc. Platelet membrane microparticles
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
WO1992008349A1 (en) 1990-11-07 1992-05-29 Baxter International Inc. Blood platelet storage medium
EP0564502B1 (de) 1990-11-27 2002-01-30 The American National Red Cross Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
GB9114202D0 (en) 1991-07-01 1991-08-21 Quadrant Holdings Cambridge Blood products
WO1993014191A1 (en) 1992-01-21 1993-07-22 Cryopharm Corporation Method of freezing cells and cell-like materials
US5423738A (en) 1992-03-13 1995-06-13 Robinson; Thomas C. Blood pumping and processing system
DE69333924T2 (de) 1992-05-29 2006-08-17 University Of North Carolina At Chapel Hill Im immobilisierten Zustand getrocknete pharmazeutisch verträgliche menschliche Blutplättchen
ATE199626T1 (de) 1993-06-04 2001-03-15 Biotime Inc Plasma-artige lösung
JP3788522B2 (ja) 1994-02-22 2006-06-21 日本電信電話株式会社 血球、幹細胞、および血小板の凍結乾燥生成物の製造方法
EP0668013B1 (de) 1994-02-22 2005-04-20 Nippon Telegraph And Telephone Corporation Gefriergetrocknete Blutzellen, Stammzellen und Plättchen und Verfahren zu deren Herstellung
US5656598A (en) 1994-03-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Use of fibroblast growth factors to stimulate bone growth
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5919614A (en) 1994-10-19 1999-07-06 Lifecell Corporation Composition comprising three platelet lesion inhibitors for platelet storage
US5622867A (en) 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
US20010046487A1 (en) 1994-12-30 2001-11-29 Roser Bruce J. Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby
US5736313A (en) 1995-10-20 1998-04-07 The United States Of America As Represented By The Secretary Of The Navy Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing
AU3214597A (en) 1996-05-29 1998-01-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
DE19634313A1 (de) 1996-08-24 1998-02-26 Behringwerke Ag Methode zur Stabilisierung von Plättchen
US5827741A (en) 1996-11-19 1998-10-27 The Regents Of The University Of California Cryopreservation of human adult and fetal pancreatic cells and human platelets
US5817381A (en) 1996-11-13 1998-10-06 Agricultural Utilization Research Institute Cellulose fiber based compositions and film and the process for their manufacture
US6139878A (en) 1998-04-27 2000-10-31 Aventis Behring, Llc Method for preparing a diafiltered stabilized blood product
ATE235915T1 (de) 1998-11-20 2003-04-15 Lilly Co Eli Behandlung von hämorrhagischem virusfieber mit protein c
EP1374890A3 (de) 1999-01-28 2004-08-25 Board Of Regents, The University Of Texas System Thrombopoietinzusammensetzungen zur Verhöhung von zirkulierenden Plättchen
WO2001007921A2 (en) 1999-07-23 2001-02-01 Medical Analysis Systems, Inc. Stabilized coagulation control reagent
WO2001010421A1 (en) 1999-08-06 2001-02-15 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US7033603B2 (en) 1999-08-06 2006-04-25 Board Of Regents The University Of Texas Drug releasing biodegradable fiber for delivery of therapeutics
US6211575B1 (en) 1999-08-18 2001-04-03 Sigmatel Inc. Method and apparatus for identifying customized integrated circuits
DE60002103T2 (de) 1999-11-12 2003-12-18 Elan Drug Delivery Ltd., Ruddington Stabilisierung von blutplättchen
US7208265B1 (en) 1999-11-24 2007-04-24 Xy, Inc. Method of cryopreserving selected sperm cells
ITAL990010U1 (it) 1999-12-14 2001-06-14 Maria Cristina Sacchi Nuova metodica di laboratorio per preparare gel e membrane piastriniche ottenute dal concentrato piastrinico.
US20040185524A1 (en) 2000-02-10 2004-09-23 Crowe John H. Biological samples and method for increasing survival of biological samples
CA2397362A1 (en) 2000-02-10 2001-08-16 The Regents Of The University Of California Therapeutic platelets and methods
US6770478B2 (en) 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US20040147024A1 (en) 2000-02-10 2004-07-29 Crowe John H. Therapeutic platelets and methods
US20020076445A1 (en) 2000-02-10 2002-06-20 Crowe John H. Eukaryotic cells and method for preserving cells
US20040152964A1 (en) 2000-02-10 2004-08-05 Crowe John H. Method and therapeutic platelets
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US20010043943A1 (en) 2000-05-22 2001-11-22 Coffey Arthur C. Combination SIS and vacuum bandage and method
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
ATE445418T1 (de) 2000-10-19 2009-10-15 Bracco Imaging Spa Radiopharmazeutische formulierungen
US20050222029A1 (en) 2001-01-04 2005-10-06 Myriad Genetics, Incorporated Compositions and methods for treating diseases
DK2574662T3 (da) 2001-08-22 2021-09-20 Maxcyte Inc Fremgangsmåde til elektroporation af biologiske prøver
EP1446148A1 (de) 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure
US20040136974A1 (en) 2002-01-16 2004-07-15 Crowe John H. Therapeutic platelets and methods
JP2003238174A (ja) 2002-02-15 2003-08-27 Asahi Glass Co Ltd フロートガラスの製造方法
US7806845B2 (en) 2002-04-24 2010-10-05 Biomet Biologics, Llc Blood separation and concentration system
JP4699028B2 (ja) 2002-11-08 2011-06-08 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 血小板の生存を延長するための組成物および方法
WO2004050896A2 (en) 2002-11-29 2004-06-17 The Regents Of The University Of California A method and therapeutic platelets
AU2003304289A1 (en) 2002-11-29 2005-01-21 The Regents Of The University Of California A method and therapeutic platelets
GB0305133D0 (en) 2003-03-06 2003-04-09 Sinvent As Product
US7294455B2 (en) 2003-05-16 2007-11-13 The University Of North Carolina At Chapel Hill Fixed-dried platelets cross-linked to protein
US20050048460A1 (en) 2003-05-29 2005-03-03 The Regents Of The University Of California Preservative and method for preserving cells
US20060200100A1 (en) 2003-06-18 2006-09-07 Rosati Coni F Method and apparatus for supplying gas to an area
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
JP2005053841A (ja) 2003-08-05 2005-03-03 Kyouto Biomedical Science:Kk 皮膚外用剤
WO2005020893A2 (en) 2003-08-06 2005-03-10 The Regents Of The University Of California Therapeutic platelets and methods
GB0323378D0 (en) 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
WO2005065242A2 (en) 2003-12-29 2005-07-21 Am Biosolutions Method of treating cancer using platelet releasate
US20050191286A1 (en) 2004-02-09 2005-09-01 Gandy James B. Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair
CA2563904A1 (en) 2004-02-18 2005-08-25 Plasma Ventures Pty Ltd Isolated plasma and method for hyperimmunisation and plasma collection
US20060035383A1 (en) 2004-08-12 2006-02-16 David Ho Dry platelet preparations for use in diagnostics
US20060051731A1 (en) * 2004-08-12 2006-03-09 David Ho Processes for preparing lyophilized platelets
US7811558B2 (en) 2004-08-12 2010-10-12 Cellphire, Inc. Use of stabilized platelets as hemostatic agent
US20060095121A1 (en) 2004-10-28 2006-05-04 Medtronic Vascular, Inc. Autologous platelet gel on a stent graft
WO2006059329A1 (en) 2004-12-01 2006-06-08 Hadasit Medical Research Services & Development Limited Platelet-derived microparticles for therapy
US20080299212A1 (en) 2005-02-25 2008-12-04 Medigenes Co., Ltd Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum
WO2008048228A2 (en) 2005-08-12 2008-04-24 Department Of The Army Glycine stabilized lyophilized plasma
WO2008048229A2 (en) 2005-08-12 2008-04-24 Department Of The Army Stabilized lyophilized blood platelets
US20090035289A1 (en) 2005-09-26 2009-02-05 Lifecell Corporation Dry platelet composition
US20070087061A1 (en) 2005-10-14 2007-04-19 Medafor, Incorporated Method and composition for creating and/or activating a platelet-rich gel by contact with a porous particulate material, for use in wound care, tissue adhesion, or as a matrix for delivery of therapeutic components
US20070178104A1 (en) 2006-01-31 2007-08-02 Awdalla Essam T Methods and means for treating solid tumors
CA2646491A1 (en) 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
US20070243137A1 (en) 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
US8529959B2 (en) 2006-10-17 2013-09-10 Carmell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8790924B2 (en) 2006-10-19 2014-07-29 Duke University Reversible platelet inhibition
WO2008073491A1 (en) 2006-12-11 2008-06-19 University Of Florida Research Foundation, Inc. System and method for analyzing progress of labor and preterm labor
US8097403B2 (en) 2006-12-14 2012-01-17 Cellphire, Inc. Freeze-dried platelets, method of making and method of use as a diagnostic agent
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
US20110020107A1 (en) 2007-03-23 2011-01-27 Flodesign Wind Turbine Corporation Molded wind turbine shroud segments and constructions for shrouds
US8512697B2 (en) 2007-05-16 2013-08-20 The University Of North Carolina At Chapel Hill Delivery of micro- and nanoparticles with blood platelets
DE102007028090A1 (de) 2007-06-12 2008-12-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Aktivierbare diagnostische und therapeutische Verbindung
WO2009040020A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
WO2009049318A2 (en) 2007-10-12 2009-04-16 Bakaltcheva Irina B Freeze-dried plasma formats for the trauma care field
US8137975B2 (en) 2007-10-29 2012-03-20 Beckman Coulter, Inc. Method for a rapid antibody-based analysis of platelet populations
US20110008804A1 (en) 2007-11-05 2011-01-13 Kain Kevin C Angiopoietin-1 and -2 biomarkers for infectious diseases that compromise endothelial integrity
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
TW200930811A (en) 2008-01-04 2009-07-16 Univ Nat Taiwan Science Tech Transfection reagent and method for enhancing transfection efficiency
EP2077118A1 (de) 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Gerinnungsfähiges Konzentrat von Plättchenwachstumsfaktoren und Herstellungsverfahren dafür
EP2620139B1 (de) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1-Rezeptorantagonisten-reiche Lösungen
EP2286223B1 (de) 2008-05-02 2016-07-06 University Of Rochester Detektorsystem in arrayform zur messung einer influenza-immunantwort
US20100055067A1 (en) 2008-08-26 2010-03-04 Snu R&Db Foundation Perfluorocarbon conjugate as a blood substitute
WO2010046949A1 (ja) 2008-10-22 2010-04-29 Inui Hiroaki 細胞をガラス化保存する方法および細胞のガラス化保存用容器
EP2391341A4 (de) 2009-01-30 2012-05-09 Cuthbert O Simpkins Wiederbelebungsflüssigkeit
CN102317447B (zh) 2009-05-07 2015-06-10 加米达细胞有限公司 用于筛选扩增的干细胞群的方法
US8715920B2 (en) 2010-07-27 2014-05-06 Biovec Transfusion, Llc Composition for preserving platelets during photosensitization
EP2266635A1 (de) 2009-06-26 2010-12-29 Aarhus Universitet Hybridgerüst mit dreidimensionaler Nanostruktur und Herstellung davon
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
EP2521444A2 (de) 2010-01-07 2012-11-14 Core Dynamics Ltd Verfahren zum präsevieren von knochenspongiosaproben und präserviertes knochenspongiosagewebe
US20110183311A1 (en) 2010-01-27 2011-07-28 David Ho Dry platelet preparations for use in diagnostics
WO2011103114A1 (en) 2010-02-17 2011-08-25 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
EP2555918A1 (de) 2010-04-06 2013-02-13 Genvault Corporation Stabilisierte chemische dehydrierung biologischer materialien
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
WO2012050611A2 (en) 2010-10-13 2012-04-19 Duke University Aptamers to glycoprotein vi
CN103476932A (zh) 2010-10-14 2013-12-25 雷加多生物科学公司 Clec-2的核酸调节剂
US20140083628A1 (en) 2012-09-27 2014-03-27 Velico Medical, Inc. Spray drier assembly for automated spray drying
WO2012071135A2 (en) 2010-11-23 2012-05-31 Biovec Transfusion, Llc Methods for removing pathogens from a platelet preparation
US20120134974A1 (en) 2010-11-30 2012-05-31 Biovec Transfusion, Llc Methods for removing plasma
IL210162A0 (en) 2010-12-21 2011-03-31 Omrix Biopharmaceuticals Viral inactivated platelet extract, use and preparation thereof
JP2012143554A (ja) 2010-12-24 2012-08-02 Toray Ind Inc ポリスルホン系中空糸膜及び血小板浮遊液浄化用中空糸膜モジュール並びに血小板浮遊液の浄化方法
JP2014518547A (ja) 2011-04-07 2014-07-31 フェンウォール、インコーポレイテッド 削減された残存血漿容積を有する血小板濃縮物を提供するための自動化方法とシステムおよびそのような血小板濃縮物のための貯蔵媒体
US20120321601A1 (en) 2011-05-17 2012-12-20 Qiyong Peter Liu Increased In Vivo Circulation Time of Platelets After Storage With A Sialidase Inhibitor
ES2811085T7 (es) 2011-06-27 2021-11-29 Univ Emory Composiciones, usos y preparación de lisados de plaquetas
CA2884836C (en) 2011-09-14 2018-01-23 Brian Anthony LEMPER Inhalation systems, breathing apparatuses, and methods
KR101410065B1 (ko) 2011-12-09 2014-06-27 테고사이언스 (주) 세포의 유용물질을 상온에서 안정하게 보존하는 방법
US9682104B2 (en) 2012-01-26 2017-06-20 Jadi Cell Llc Lyophilized platelet lysates
CN103524613A (zh) 2012-07-04 2014-01-22 晶光源生技股份有限公司 皮肤更新生长因子及其于皮肤保养的用途及含其的保养品
WO2014051537A1 (en) 2012-09-25 2014-04-03 Biovec Transfusion, Llc Device and method for removing additives in the blood products
EP2903646A1 (de) 2012-10-04 2015-08-12 Genesys Research Institute Kaffeezusammensetzungen und verwendungen davon
WO2014066142A1 (en) 2012-10-24 2014-05-01 Novamedica Limited Liability Company Nucleic acid regulation of growth arrest-specific protein 6 (gas6)
WO2014066663A1 (en) 2012-10-24 2014-05-01 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
EP2926820B1 (de) 2012-11-30 2017-08-30 Toray Industries, Inc. Verfahren zur herstellung einer mit künstlicher konservierungslösung ersetzten thrombozytenlösung
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
ITRM20130054A1 (it) 2013-01-30 2014-07-31 Paolo Gresele Piastrine trasfettate con materiale genetico esogeno e microparticelle derivate da dette piastrine trasfettate, metodo per la loro preparazione e loro usi.
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
CA2922634A1 (en) 2013-08-27 2015-03-05 Mayo Foundation For Medical Education And Research Cross-linked platelet material
WO2015041628A1 (en) 2013-09-17 2015-03-26 Becton, Dickinson And Company Stabilization of blood ph during sample storage
US20160235781A1 (en) 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
EP3063544B1 (de) 2013-10-29 2021-05-26 Versiti Blood Research Institute Foundation, Inc. Verfahren zum nachweis von thrombozytenaktivierenden antikörpern als verursacher von heparininduzierter thrombozytopenie/thrombose
EP3071515A2 (de) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetische membran-empfänger-komplexe
WO2015109220A1 (en) 2014-01-17 2015-07-23 President And Fellows Of Harvard College Platelet decoy and use thereof
CN103907595A (zh) 2014-04-18 2014-07-09 赵树铭 含海藻糖的血小板低温保存液及其应用
EP3769618A1 (de) 2014-06-09 2021-01-27 Terumo BCT, Inc. Behälter zur lyophilisierung
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
ES2884256T3 (es) 2014-06-10 2021-12-10 Biomatrica Inc Métodos y composiciones para la estabilización de ácidos nucleicos en una muestra de sangre a temperaturas ambientales
WO2016014854A1 (en) 2014-07-23 2016-01-28 Cerus Corporation Methods for preparing platelet products
US20170274012A1 (en) 2014-09-03 2017-09-28 Entegrion, Inc. Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
WO2016057041A1 (en) 2014-10-09 2016-04-14 Biovec Transfusion, Llc Compositions and methods for preserving platelet function
US20170333593A1 (en) 2014-11-14 2017-11-23 Cellphire, Inc. Products and devices for controlling and stopping bleeding and methods of using
CN107405391B (zh) 2015-03-04 2021-03-19 罗切斯特大学 治疗外伤患者中的出血的血小板微粒的全身和局部应用
WO2016164693A1 (en) 2015-04-10 2016-10-13 Board Of Regents, The University Of Texas System Compositions and methods for prolonged cell storage
WO2016201081A1 (en) 2015-06-10 2016-12-15 Cellphire, Inc. Composition and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
WO2016205144A1 (en) 2015-06-14 2016-12-22 Bluecircle Therapeutics, Inc. Compositions of platelet-derived theranostics and uses thereof
US11224577B2 (en) 2015-06-19 2022-01-18 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles
CN108136023B (zh) 2015-08-12 2021-07-27 北卡罗莱纳州立大学 血小板膜包覆的药物递送系统
US20200281980A1 (en) 2015-08-28 2020-09-10 Cellphire, Inc. Products and methods using a platelet-derived hemostatic agent for controlling bleeding and improving healing
US20230248772A1 (en) 2015-08-28 2023-08-10 Cellphire, Inc. Products and methods using a platelet-derived hemostatic agent for controlling bleeding and improving healing
US12318489B2 (en) 2015-10-26 2025-06-03 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
EP3377645B1 (de) 2015-11-20 2023-10-04 Qiagen GmbH Verfahren zur herstellung sterilisierter zusammensetzungen zur stabilisierung von extrazellulären nukleinsäuren
WO2017123539A1 (en) 2016-01-14 2017-07-20 Cellphire, Inc. Nucleated cell preservation by lyophilization
EP3506915B1 (de) 2016-09-01 2024-03-06 Plas-Free Ltd Aus menschlichem blut gewonnene produkte mit verringerter fibrinolytischer aktivität und verwendungen davon in hämostatischen störungen
TWI664412B (zh) 2016-10-04 2019-07-01 全崴生技股份有限公司 維持細胞活性之組成物和方法
WO2018084228A1 (ja) 2016-11-04 2018-05-11 国立大学法人東京大学 動物細胞又は動物組織の凍結保存用溶液、凍結物、及び凍結保存方法
AU2016431615A1 (en) 2016-12-08 2019-06-20 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
US20190076478A1 (en) 2017-09-13 2019-03-14 Cellphire, Inc. Canine blood platelet preparations
US20230112136A1 (en) 2017-09-13 2023-04-13 Cellphire, Inc. Canine blood platelet preparations
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
CN108715834B (zh) 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
US20200046771A1 (en) 2018-07-27 2020-02-13 Cellphire, Inc. Cryopreserved platelet compositions and methods for making
CA3015457A1 (en) 2018-08-24 2020-02-24 Bloodworks Methods to reduce clot formation in cold-stored platelet products
US20200060262A1 (en) 2018-08-24 2020-02-27 Bloodworks Methods to reduce clot formation in cold-stored platelet products
US11088715B2 (en) 2018-08-31 2021-08-10 TE Connectivity Services Gmbh Communication system having a receptacle cage with an airflow channel
CA3112455A1 (en) 2018-09-11 2020-03-19 Cellphire, Inc. Blood plasma-containing compositions
CN109942687B (zh) 2018-10-16 2020-07-03 哈尔滨医科大学 68Ga标记EACA修饰c-Met分子成像探针及制备与应用
US20230248771A1 (en) 2018-11-30 2023-08-10 Cellphire, Inc. Platelets loaded with anti-cancer agents
AU2019387368A1 (en) 2018-11-30 2021-06-17 Cellphire, Inc. Platelets as delivery agents
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
CA3129450A1 (en) 2019-02-13 2020-08-20 Tigenix, S.A.U. Cryopreservation of stem cells
EP3937631A4 (de) 2019-03-13 2023-01-04 Cellphire Inc. Blutplättchenpräparationen vom hund
WO2020219557A1 (en) 2019-04-22 2020-10-29 The George Washington University Magnetic platelet probes to detect circulating tumor cells
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
WO2021011857A1 (en) 2019-07-17 2021-01-21 Cellphire, Inc. Use of platelets in treating infections
WO2023081804A1 (en) 2021-11-04 2023-05-11 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions
WO2023220739A1 (en) 2022-05-12 2023-11-16 Cellphire, Inc. Platelet derivative compositions for use in subjects afflicted with hermansky pudlak syndrome or bernard soulier syndrome
WO2022178177A1 (en) 2021-02-17 2022-08-25 Cellphire, Inc. Freeze-dried platelet derivative compositions for treating antiplatelet-induced coagulopathy
US20220168353A1 (en) * 2019-08-16 2022-06-02 Cellphire Inc. Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy
CA3150936A1 (en) * 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
EP4013432A4 (de) 2019-08-16 2023-10-18 Cellphire Inc. Thrombosomen als mittel zur aufhebung der gerinnungshemmenden wirkung
US20240066065A1 (en) 2019-08-16 2024-02-29 Cellphire, Inc. Platelet derivatives for treating coagulopathy
US20210069240A1 (en) 2019-09-05 2021-03-11 Cellphire, Inc. Materials and methods for blood plasma preparations
WO2021108538A1 (en) 2019-11-27 2021-06-03 Cellphire, Inc. PLATELETS LOADED WITH mRNA
EP4065175A4 (de) 2019-11-27 2023-12-06 Cellphire, Inc. Diagnostische thrombozyten-kontrastmittel
EP4101056A4 (de) 2020-02-03 2024-02-28 Malta Inc. Gepumptes elektrisches wärmespeichersystem mit doppelkupplungsantriebssystem
CA3170198A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets
WO2021232015A1 (en) 2020-05-15 2021-11-18 Cellphire, Inc. Platelet derived extracellular vesicles
US20220211029A1 (en) 2020-11-10 2022-07-07 Cellphire, Inc. Freeze-dried peripheral blood mononuclear cell compositions and methods
WO2022178191A1 (en) 2021-02-17 2022-08-25 Cellphire, Inc. Freeze-dried platelet derivative compositions for treating anticoagulant-induced coagulopathy
US20220273724A1 (en) * 2021-02-17 2022-09-01 Cellphire Inc. Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy
US20220279777A1 (en) 2021-02-17 2022-09-08 Cellphire Inc. Freeze-dried platelet derivative compositions for treating anticoagulant-induced coagulopathy
US20230149467A1 (en) 2021-11-04 2023-05-18 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions
WO2023220694A1 (en) 2022-05-12 2023-11-16 Cellphire, Inc. Mri-agent loaded platelet compositions and methods of preparing and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0967862A1 (de) * 1997-02-07 2000-01-05 Quadrant Holdings Cambridge Limited Verfahren und zusammensetzungen zur herstellung getrockneter, lagerungsstabiler blutplättchen
US8486617B2 (en) * 2004-08-12 2013-07-16 Cellphirc, Inc Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use

Also Published As

Publication number Publication date
IL290586B1 (en) 2025-08-01
CA3150936A1 (en) 2021-02-25
US12419914B2 (en) 2025-09-23
AU2020334903A1 (en) 2022-03-31
US20210046121A1 (en) 2021-02-18
AU2024201792B2 (en) 2026-02-26
US12208122B2 (en) 2025-01-28
US11701388B2 (en) 2023-07-18
AU2020334903B2 (en) 2023-12-21
CN114450066A (zh) 2022-05-06
WO2021034719A1 (en) 2021-02-25
BR112022002892A2 (pt) 2022-05-24
JP7791581B2 (ja) 2025-12-24
IL290586A (en) 2022-04-01
EP4013496A1 (de) 2022-06-22
KR20220054329A (ko) 2022-05-02
US20240277771A1 (en) 2024-08-22
AU2024201792A1 (en) 2024-04-04
EP4013496A4 (de) 2023-10-18
US20230285465A1 (en) 2023-09-14
JP2022545390A (ja) 2022-10-27

Similar Documents

Publication Publication Date Title
US12419914B2 (en) Thrombosomes as an antiplatelet agent reversal agent
US20210046120A1 (en) Thrombosomes as an anticoagulant reversal agent
US20220168353A1 (en) Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy
US20220279777A1 (en) Freeze-dried platelet derivative compositions for treating anticoagulant-induced coagulopathy
US20220273724A1 (en) Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy
CN101072506B (zh) 制备冻干血小板的方法、包括冻干血小板的组合物和使用方法
WO2022178191A1 (en) Freeze-dried platelet derivative compositions for treating anticoagulant-induced coagulopathy
WO2022178177A9 (en) Freeze-dried platelet derivative compositions for treating antiplatelet-induced coagulopathy
US20210308066A1 (en) Anti-fibrinolytic loaded platelets
US20230112136A1 (en) Canine blood platelet preparations
US20250177450A1 (en) Methods for administering freeze-dried platelet derivative compositions to subjects treated with a factor xi inhibitor
CA3211079A1 (en) Freeze-dried platelet derivative compositions for treating antiplatelet-induced coagulopathy